1. Home
  2. DARE vs COHN Comparison

DARE vs COHN Comparison

Compare DARE & COHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DARE
  • COHN
  • Stock Information
  • Founded
  • DARE 2015
  • COHN 1999
  • Country
  • DARE United States
  • COHN United States
  • Employees
  • DARE N/A
  • COHN N/A
  • Industry
  • DARE Biotechnology: Pharmaceutical Preparations
  • COHN Investment Bankers/Brokers/Service
  • Sector
  • DARE Health Care
  • COHN Finance
  • Exchange
  • DARE Nasdaq
  • COHN Nasdaq
  • Market Cap
  • DARE 26.3M
  • COHN 21.6M
  • IPO Year
  • DARE N/A
  • COHN N/A
  • Fundamental
  • Price
  • DARE $2.57
  • COHN $11.83
  • Analyst Decision
  • DARE Strong Buy
  • COHN
  • Analyst Count
  • DARE 3
  • COHN 0
  • Target Price
  • DARE $12.50
  • COHN N/A
  • AVG Volume (30 Days)
  • DARE 4.5M
  • COHN 8.9K
  • Earning Date
  • DARE 08-11-2025
  • COHN 08-04-2025
  • Dividend Yield
  • DARE N/A
  • COHN 8.45%
  • EPS Growth
  • DARE N/A
  • COHN N/A
  • EPS
  • DARE N/A
  • COHN N/A
  • Revenue
  • DARE $25,909.00
  • COHN $84,171,000.00
  • Revenue This Year
  • DARE $74,787.57
  • COHN N/A
  • Revenue Next Year
  • DARE $141.76
  • COHN N/A
  • P/E Ratio
  • DARE N/A
  • COHN N/A
  • Revenue Growth
  • DARE N/A
  • COHN N/A
  • 52 Week Low
  • DARE $2.11
  • COHN $6.10
  • 52 Week High
  • DARE $9.19
  • COHN $13.25
  • Technical
  • Relative Strength Index (RSI)
  • DARE 46.85
  • COHN 75.00
  • Support Level
  • DARE $2.44
  • COHN $11.00
  • Resistance Level
  • DARE $2.80
  • COHN $13.25
  • Average True Range (ATR)
  • DARE 0.66
  • COHN 0.45
  • MACD
  • DARE 0.02
  • COHN 0.12
  • Stochastic Oscillator
  • DARE 6.50
  • COHN 54.19

About DARE Dare Bioscience Inc.

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

Share on Social Networks: